Marc R. Azar, Ph.D., is Behavioral Pharma’s Founder and Chief Scientific Officer.He holds a Ph.D. in Biobehavioral Health from The Pennsylvania State University and postdoctoral training in Neuropharmacology from The Scripps Research Institute (TSRI), offering extensive expertise in behavioral neuroscience.
Dr. Azar was a long-time collaborator with the Committee on the Neurobiology of Addictive Disorders at TSRI, after founding Behavioral Pharma in 2001. Dr. Azar focuses his research on a wide range of CNS disorders with particular focus on addiction research. With over two decades of experience, he has been the driving force behind Behavioral Pharma since its inception in 2001. His passion for collaboration and client satisfaction has fostered strong relationships with decision-makers in academia, neuroscience, biotech, and pharmaceutical industries.
Dr. Azar’s skills span executive management, strategic planning, resource targeting, regulatory compliance, and fiscal responsibility. His leadership guarantees exceptional delivery of in-vivo preclinical testing services. Emphasizing custom attention to protocol development and implementation, he minimizes costs while maximizing productivity for clients.